MindWalk Holdings Corp. (HYFT)
NASDAQ: HYFT · Real-Time Price · USD
1.870
-0.010 (-0.53%)
At close: Oct 8, 2025, 4:00 PM EDT
1.851
-0.019 (-1.03%)
After-hours: Oct 8, 2025, 7:55 PM EDT
MindWalk Holdings Revenue
MindWalk Holdings had revenue of 3.16M CAD in the quarter ending July 31, 2025, with 27.82% growth. This brings the company's revenue in the last twelve months to 25.21M, up 18.33% year-over-year. In the fiscal year ending April 30, 2025, MindWalk Holdings had annual revenue of 24.52M with 0.01% growth.
Revenue (ttm)
25.21M CAD
Revenue Growth
+18.33%
P/S Ratio
3.94
Revenue / Employee
247,137 CAD
Employees
102
Market Cap
86.31M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 24.52M | 2.00K | 0.01% |
| Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
| Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
| Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
| Apr 30, 2021 | 17.91M | 3.85M | 27.42% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HYFT News
- 16 days ago - MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity - Business Wire
- 23 days ago - MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 23 days ago - MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet - Business Wire
- 5 weeks ago - ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” - Business Wire
- 5 weeks ago - ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York - Business Wire
- 6 weeks ago - ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation - Business Wire
- 2 months ago - AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd. - Business Wire
- 2 months ago - ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation - Business Wire